Tamtam Try Tamtam free
AdaptHealth logo

AdaptHealth account plan

Medical equipment distribution and services

At a glance

AdaptHealth is a US home medical equipment and supplies provider: $3,244.9 million FY2025 revenue, about 10,900 employees, 4.8 million patients a year.

AdaptHealth Corp., headquartered in Conshohocken, Pennsylvania, delivers home medical equipment, medical supplies and related services to patients at home after hospital discharge or physician referral, billing Medicare, Medicaid and commercial payors. As of September 30, 2026 it served approximately 4.8 million patients annually through approximately 660 locations in 48 states. FY2025 net revenue was $3,244.9 million (down 0.5%), Adjusted EBITDA $616.7 million and the net loss attributable to AdaptHealth $70.8 million after a goodwill impairment. It had approximately 10,900 employees at December 31, 2025, plus about 4,400 outsourced full-time-equivalent staff in India and the Philippines; all operations are in the United States.

Business units

Strategic priorities

Making the large capitated contract profitable
The contract with Kaiser on the West Coast reached a margin of about 10% in Q3 2026 from -4% in Q2, exiting at a 14% run rate; the target is a 20% margin by Q4 2027, before any repricing.
Focus on Sleep, Respiratory and Wellness at Home
With the Diabetes Health sale, AdaptHealth becomes a three-segment business; about $60 million of overhead previously allocated to Diabetes Health has to be cut or absorbed.
Deleveraging to 2.5x
Net debt was $1.85 billion with total leverage of 3.05x after Q3 2026; the target is 2.5x, with a significant portion of the Diabetes Health proceeds going to debt reduction.
Growing capitated and enterprise business
An enterprise sales team signed four preferred-provider agreements with health systems, and two regional capitated agreements cover 72,000 exclusive lives.
Technology and AI in workflows
AI pilots for sleep order intake and PAP self-scheduling are being expanded in 2026; myAPP has more than 615,000 registered users and the AI mask-fitting tool has completed more than 12,600 scans.

Latest results

In Q3 2026 net revenue from continuing operations was $745.6 million, up 10.9% (organic +12.8%), with capitated revenue rising to $110.3 million, 14.8% of net revenue. Adjusted EBITDA was $141.9 million (19.0% margin vs 21.7%), $11.2 million above the guidance midpoint. The net loss attributable to AdaptHealth was $168.2 million after a $184.8 million goodwill impairment on Respiratory Health and Wellness at Home. Nine-month free cash flow fell to $2.6 million from $140.1 million on equipment bought for capitated contracts. 2026 guidance is net revenue of $2.88-$2.90 billion, Adjusted EBITDA of $510-$525 million and free cash flow of $55-$80 million, down from the February guidance of $3.44-$3.51 billion revenue.

Investments and deals

Diabetes Health divestment
Sale for $235.0 million in cash agreed July 19, 2026; the Hart-Scott-Rodino waiting period has expired and closing is expected in Q1 2027.
Capitated-contract asset purchases
Assets bought from two previous providers in four transactions for $127.3 million in cash in 2026, to transition patients under newly awarded capitated contracts.
2026 refinancing
A 2026 Credit Agreement (April 10, 2026) of a $325.0 million term loan, a $325.0 million delayed draw term loan and a $450.0 million revolver; the $325.0 million 6.125% Senior Notes were redeemed on August 3, 2026.
Cost-reduction plan
A June 2026 plan with headcount cuts and the wind-down of an immaterial business cost $6.1 million and targets about $26.8 million of annual savings.
Portfolio pruning in 2025
Incontinence and infusion businesses were sold in 2025 (gross proceeds $69.1 million and $53.5 million); the eCommerce subsidiary was contributed to a joint venture in July 2026.

Challenges and risks

Capitated contract costs
Utilization was higher than expected from day one and the cost to serve at the partner's hospitals was not assumed in pricing; capex is running at 14.2% of net revenue.
Supplier pricing and concentration
A manufacturer terminated its contract on June 30, 2026 with an immediate price increase estimated at about $30 million of second-half Adjusted EBITDA, and Medline is removing its beds from the market; AdaptHealth buys most categories from two to three suppliers.
Reimbursement and regulation
Dependence on Medicare, Medicaid and private payors, the resumption of the DMEPOS Competitive Bidding Program (contracts in effect no later than January 1, 2028) and two open False Claims Act civil investigative demands.
Cyber security
A social-engineering attack disclosed on July 2, 2026 led to exfiltration of patient information and a stored insurance-billing password file.
Stranded cost and margin pressure
About $30 million of overhead from Diabetes Health is "true stranded cost"; the nine-month 2026 Adjusted EBITDA margin was 17.5% vs 20.0%.

What leadership says

“we are a focused Sleep, Respiratory, and Wellness at Home business, where growth and margins are more attractive.”

Suzanne Foster, Chief Executive Officer · Q3 2026 earnings call, November 3, 2026

“We have been provided assurances that pricing adjustments are coming”

Suzanne Foster, Chief Executive Officer · Q3 2026 earnings call, November 3, 2026, on the large capitated contract

“Our new capitated contract is a massive undertaking, the largest service transition in the HME industry's history.”

Suzanne Foster, Chief Executive Officer · Q4 and full-year 2025 earnings call, February 24, 2026

Where a supplier can help

Labor efficiency on the capitated contract
Tied to the 20% margin target on the large capitated contract: workforce scheduling, logistics and automation tools that lower cost to serve match the tighter labor model the company is running.
Alternative equipment suppliers
Tied to the manufacturer price increase and Medline's bed exit: suppliers of PAP devices, beds and other HME can offer diversification the company has already begun.
Security and identity protection
Tied to the 2026 social-engineering cyber incident: identity, access and security awareness services address the attack vector described.
AI and digital patient workflows
Tied to the AI order-intake and self-scheduling rollout: conversational AI, intake automation and patient app vendors fit a stated 2026 expansion.
Overhead reduction after the Diabetes sale
Tied to the $60 million of overhead to cut or absorb: outsourcing, back-office and IT consolidation offers can help remove stranded cost.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like AdaptHealth?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about AdaptHealth

What does AdaptHealth do?

AdaptHealth provides home medical equipment, medical supplies and related services such as CPAP, oxygen and hospital beds to patients at home across the United States.

What was AdaptHealth's revenue in 2025?

FY2025 net revenue was $3,244.9 million, down 0.5%, with Adjusted EBITDA of $616.7 million.

How many employees does AdaptHealth have?

About 10,900 employees at December 31, 2025, plus about 4,400 outsourced full-time-equivalent staff; group headcount was 10,995 after Q3 2026 according to the earnings call.

Who leads AdaptHealth?

Suzanne Foster is Chief Executive Officer; Harriss Currie became CFO in September 2026, succeeding Jason Clemens.

Is AdaptHealth selling its diabetes business?

Yes. Diabetes Health is being sold for $235.0 million in cash, with closing expected in Q1 2027.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)